Keywords: gemzar, nsclc, eli, lilly, gemcitabine, combination, cisplatin
Gemzar In NSCLC
Article | 27 January 1997
Eli Lilly's Gemzar (gemcitabine) in combination with cisplatin hasachieved a 54% overall response rate in patients with non-small cell lung cancer, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
